Neuroendocrinology

The American Journal of Managed Care® (AJMC®)’s Institute for Value-Based Medicine® (IVBM®) hosts event to highlight treatment options for obesity and minimizing risk of type 2 diabetes and cardiovascular disease

Retrieved on: 
Friday, April 5, 2024
American Heart Association, Cardiovascular disease, Obesity, Public health, UH, Type 2 diabetes, Risk, Partnership, DSM-IV codes, Integration, Harvard University, American Journal, Central nervous system, Diabetes, Health, Research, Travel, Neuroendocrinology, Role, Doctor of Public Health, MBA, WTW, Campbell University, CINEMA, MSL

The Institute for Value-Based Medicine® (IVBM®) has gained recognition for advocating value-based care and advancing health care methodologies.

Key Points: 
  • The Institute for Value-Based Medicine® (IVBM®) has gained recognition for advocating value-based care and advancing health care methodologies.
  • The upcoming event will showcase a panel of health care experts engaging in discussions about the latest advancements in the fields of value-based care and population health practices.
  • The event aims to acknowledge and explore the challenges within these domains.
  • Their invaluable insights and contributions will enrich the event, making it an exceptional platform for cutting-edge discussions in the health care landscape.

Visionary $15 Million Gift from Wayne & Wendy Holman to NYU Langone Health Ensures Continued Excellence in Newly Named Holman Division of Endocrinology, Diabetes & Metabolism

Retrieved on: 
Wednesday, March 20, 2024
Health, Obesity, Internal medicine, Growth, NYU Langone Health, Caregiver, Physician, Trustee, Metabolism, Education, Patient, Knowledge, Research, Diabetes, NYU, Ridgeback Biotherapeutics, Neuroendocrinology, News, Infection, Thyroid disease, Cancer, Alumni, Medicine, Pharmaceutical industry

NEW YORK, March 20, 2024 /PRNewswire/ -- NYU Langone Health has received a $15 million gift from innovators and philanthropists Wayne G. Holman, MD , and Wendy Holman to further elevate the world-class treatment and study of endocrine disorders in the newly named and endowed Holman Division of Endocrinology, Diabetes & Metabolism.

Key Points: 
  • NEW YORK, March 20, 2024 /PRNewswire/ -- NYU Langone Health has received a $15 million gift from innovators and philanthropists Wayne G. Holman, MD , and Wendy Holman to further elevate the world-class treatment and study of endocrine disorders in the newly named and endowed Holman Division of Endocrinology, Diabetes & Metabolism.
  • "Wayne and Wendy's generosity in this important area of medicine will help NYU Langone further enhance our exceptional research, education and clinical care within the Holman Division of Endocrinology, Diabetes & Metabolism," said Robert I. Grossman, MD , dean and CEO, NYU Langone.
  • "I am excited for the medical advances that will undoubtedly come about because of the Holmans' deep investment."
  • The Holman Division of Endocrinology, Diabetes, & Metabolism, part of the Department of Medicine at NYU Grossman School of Medicine, is among the best in the country, ranked No.

The Paul G. Allen Family Foundation awards $10.5 million to new Allen Distinguished Investigators

Retrieved on: 
Tuesday, November 21, 2023
Medicine, Brain, Genetics, Research, Behavior, Reproduction, Hormone, Immune system, Inflammation, Testosterone, Allen Institute, EVS, Immunity, Microscopy, B cell, Disease, Protein, Learning, Mortality, Cardiovascular disease, Glossary of biology, Extracellular vesicle, Lipoprotein, Male, Neuron, Map, Animal, Machine learning, Health, COVID-19, Seminal vesicles, Ageing, Administration, Infection, Estradiol, Mammal, Neuroendocrinology, EV, DSM-IV codes, Skin, Female, Innovation, Cell, Biology, Traffic barrier, Pharmaceutical industry, Vaccine, Fireworks, Birth control, Science

18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology

Key Points: 
  • 18 researchers will develop technologies, design approaches and uncover insights into fundamental areas of human biology
    The Paul G. Allen Family Foundation will award $1.5 million to seven research projects which 18 researchers will lead.
  • "Our two newest cohorts of Allen Distinguished Investigators are using innovative technologies and unprecedented ambition to pioneer new frontiers in the fields of sex hormones and extracellular vesicles.
  • said Kathy Richmond , Ph.D., M.B.A., Executive Vice President and Director of the Frontiers Group and the Office of Science and Innovation at the Allen Institute.
  • Including the new awards, a total of 130 Allen Distinguished Investigators have been appointed during the past 12 years.

Alacrita Consulting Promotes Saadia Basharat & Jess Hearn-Messenger to Principals

Retrieved on: 
Thursday, October 5, 2023
Jess, University of Leicester, Doctor of Philosophy, Lead, Imperial College London, Health informatics, Master of Science, Therapy, WMG, University of Warwick, University, Systems biology, Growth, VCS, Biochemistry, Monte Carlo, Pharmaceutical industry, Nursing, Neuroendocrinology, Saadia Gaon, Molecular medicine

LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.

Key Points: 
  • LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.
  • In recognition of her successful transition to San Diego, as Alacrita's Head of West Coast Consulting, she has been made a Principal of the firm.
  • We are delighted to promote her to Principal," said Alastair Southwell, Managing Partner at Alacrita Consulting.
  • Additional information on Saadia Basharat, PhD, Principal: https://www.alacrita.com/consultants/saadia-basharat
    Additional information on Jess Hearn-Messenger, PhD, Principal: https://www.alacrita.com/consultants/jess-hearn-messenger

Alacrita Consulting Promotes Saadia Basharat & Jess Hearn-Messenger to Principals

Retrieved on: 
Thursday, October 5, 2023
Jess, University of Leicester, Doctor of Philosophy, Lead, Imperial College London, Health informatics, Master of Science, Therapy, WMG, University of Warwick, University, Systems biology, Growth, VCS, Biochemistry, Monte Carlo, Pharmaceutical industry, Nursing, Neuroendocrinology, Saadia Gaon, Molecular medicine

LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.

Key Points: 
  • LONDON, Oct. 5, 2023 /PRNewswire/ -- Alacrita Consulting, a leading pharmaceutical and biotech consulting firm headquartered in London, today announces the promotions of Saadia Basharat, PhD, and Jess Hearn-Messenger, PhD, both to Principal.
  • In recognition of her successful transition to San Diego, as Alacrita's Head of West Coast Consulting, she has been made a Principal of the firm.
  • We are delighted to promote her to Principal," said Alastair Southwell, Managing Partner at Alacrita Consulting.
  • Additional information on Saadia Basharat, PhD, Principal: https://www.alacrita.com/consultants/saadia-basharat
    Additional information on Jess Hearn-Messenger, PhD, Principal: https://www.alacrita.com/consultants/jess-hearn-messenger

G8RTech, Inc. Names Its Medical Advisory Committee

Retrieved on: 
Thursday, September 14, 2023
Skiing, Snowboarding, Sports, Specialty, Consumer, Hockey, Football, Primary, Secondary, Teens, Education, Extreme Sports, Retail, Neurology, Health, BLS, USA Hockey, Concussion, Sports medicine, Fordham University, Virginia Tech, Emergency medicine, University, Neuroendocrinology, CUMC, Orthopedic surgery, Pediatrics, NewYork-Presbyterian Hospital, Impact, Massachusetts General Hospital, Harvard College, NYU Langone Health, Doctor of Philosophy, ACEP, Associate, Athlete, PPE, ACLS, MD, Hackley School, Risk, Brain, Internal medicine, Mercy College, Adolescence, Sport, Knowledge, Hospital, PALS, Nursing, Dentistry, Risk management, DRS, Neuroscience, Biochemistry, Endocrinology

G8RTech, Inc.—a specialized protective equipment company—has announced its medical advisory committee.

Key Points: 
  • G8RTech, Inc.—a specialized protective equipment company—has announced its medical advisory committee.
  • The Medical Advisory Committee is composed of Drs.
  • She pursued her undergraduate studies in Biochemistry at Harvard College and subsequently completed her medical training and residency at the Mt.
  • “We are overjoyed to announce the formation of our Medical Advisory Committee,” said Carter Hogg.

Crinetics to Highlight Broad Pipeline at ENDO 2023

Retrieved on: 
Friday, June 9, 2023
ENDO, Entrepreneurship, Maintenance, Endocrinology, Endocrine system, TSHR, Peptide hormone, FISU World University Games, Policy, Foot, Hyperparathyroidism, Saint Andrew's Society, Acromegaly, PTH1R, Physician, Pharmacokinetics, SAN, Endocrine Society, Primary hyperparathyroidism, Neuroendocrinology, Drug discovery, Medical school, Liver, SST2, Graves' ophthalmopathy, Hyperthyroidism, Memory, Pharmaceutical industry, Vaccine, Medical imaging, Safety

SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.

Key Points: 
  • SAN DIEGO, June 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced upcoming presentations that will highlight the company’s pipeline at ENDO 2023, the Endocrine Society’s annual meeting, which is being held June 15-18, 2023 in Chicago, Illinois.
  • An upcoming oral presentation will review previously reported two-year data from the company’s ACROBAT Advance open-label extension study of paltusotine in acromegaly.
  • I would like to thank the Endocrine Society for awarding this prize, which is a testament to all of the groundbreaking work being done by the Crinetics team.”
    The posters and oral presentations will be made available on the Crinetics website in accordance with the ENDO embargo policy.
  • For attendees of ENDO 2023, Crinetics staff will be available to address questions and discuss pipeline programs at the company booth (#1623).

Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, November 14, 2022
Marketing, Acromegaly, Clinical trial, ACTH, MHRA, Safety, Form 10-K, Carcinoid syndrome, SST2, Plasma, Investment, Pharmacovigilance, MAA, Congenital adrenal hyperplasia, CAH, Health care, Degenerative disease, Research, Intellectual property, COVID-19, Congenital hyperinsulinism, FDA, United Kingdom, Sequoyah, Drug Quality and Security Act, Annual report, Maintenance, Adrenocorticotropic hormone, Wilms' tumor, Therapy, Drug discovery, International Congress on Tuberculosis, Innovation, SRL, SAN, Endocrinology, Patient, Renewable energy, Pharmaceutical industry, Lease, Neuroendocrinology

SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) --  Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the third quarter ended September 30, 2022.
  • PATHFNDR-1 is one of two ongoing, placebo-controlled Phase 3 clinical trials evaluating the safety and efficacy of paltusotine in acromegaly patients.
  • Topline data from PATHFNDR-1 are expected in the third quarter of 2023 and topline data from paltusotines second Phase 3 trial, PATHFNDR-2, are expected in the fourth quarter of 2023.
  • Additional information on risks facing Crinetics can be found under the heading Risk Factors in Crinetics periodic reports, including its annual report on Form 10-K for the year ended December 31, 2021.

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

Retrieved on: 
Thursday, August 4, 2022
Metabolism, Neoplasm, Wilms' tumor, ICN, Inflammation, Degenerative disease, Congenital hyperinsulinism, Pituitary gland, Acne, Carcinoid syndrome, CAH, Blood pressure, Congenital adrenal hyperplasia, Woman, Obesity, MC2R, SAN, SST2, Acromegaly, Mental health, Glucocorticoid, ACTH, Nasdaq, Safety, Man, Androgen, Birth defect, Policy, Hypertension, Pharmacokinetics, Lists of diseases, Infertility, Insulin resistance, Hirsutism, Therapy, Drug discovery, GLOBE, International Congress on Tuberculosis, Adrenocorticotropic hormone, Pharmaceutical industry, Neuroendocrinology

August 10, 2022 at 9:00 - 10:40 a.m. BST

Key Points: 
  • August 10, 2022 at 9:00 - 10:40 a.m. BST
    Additional details on the presentation session including the presentation abstract can be accessed here .
  • The presentation will be made available on the Crinetics website in accordance with the congress embargo policy.
  • In addition, pharmacodynamic responses were evaluated before and after challenges with injected synthetic ACTH to assess pharmacologic effects resulting from exposure to CRN04894.
  • All of the companys drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts.

$4.2 Billion Worldwide Radiopharmaceuticals Industry to 2030 - Identify Growth Segments for Investment - ResearchAndMarkets.com

Retrieved on: 
Friday, April 1, 2022
Health, Pharmaceutical, Benchmark, Curium, Nephrology, Neuroendocrinology, CAGR, Radiopharmaceutical, Degenerative disease, Growth, Coronavirus, Cardiology, General Electric Company, GE, Hospital, Cancer, Cardinal Health, Prevalence, Novartis, Create, Marketing, Healthcare, Pet

Growth in the historic period resulted from rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.

Key Points: 
  • Growth in the historic period resulted from rise in healthcare expenditure, government initiatives, convenience of treatment, and changes in lifestyles.
  • Factors that could hinder the growth of the radiopharmaceuticals market in the future include high costs, supply volatility and logistical difficulties and coronavirus pandemic.
  • North America was the largest region in the global radiopharmaceuticals market, accounting for 41.6% of the total in 2020.
  • The radiopharmaceuticals market size will gain the most in the USA region at $479.9 million.